<i>Bifidobacterium longum</i> alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation
Chunhua Zhou(First Affiliated Hospital of Guangzhou Medical University), Duowu Zou(Shanghai Jiao Tong University), Jun Gao(Nanchang University), Fang Xue(Shanxi Medical University), Ling Zhang(Shanghai Jiao Tong University), Xu Han(Health and Family Planning Commission of Sichuan Province), Yu Bai(Aerospace Center Hospital), Jiulong Zhao(Second Military Medical University), Zhao‐Shen Li(Second Military Medical University), Yuting Meng(Nanjing Medical University), Wei Zhou(Broad Institute), Jiajia Xu(Nanjing Tech University)
Cited by 45
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor
|Cell Discovery|2023|329
Electrospun poly(lactic-co-glycolic acid)/halloysite nanotube composite nanofibers for drug encapsulation and sustained release
|Journal of Materials Chemistry|2010|276
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease
|Theranostics|2019|230